Phosphodiesterase 4 inhibitors have only marginal benefits for people with COPD
Giving patients with chronic obstructive pulmonary disease (COPD) newly available oral phosphodiesterase 4 (PDE4) inhibitors, roflumilast or cilomilast, improves lung function and reduces the likelihood of a flareup, but ...
May 11, 2011
0
0